Pharma & Bio
Manufacturing
"From Product Introduction to Joint Venture Establishment"... HANDOK Inc. Sees Full Effect of Its Dual-Pronged Strategy for Cancer and Rare Diseases
Mid-sized pharmaceutical company HANDOK Inc.(002390)is continuing its trend of improved performance, driven by its dual focus on anticancer drugs and treatments for rare diseases. HANDOK Inc. has trad…
Lifestyle
Merck Sets Its Sights on Injenia’s New Eye Drug ‘IGT-427’... Outperforming Eylea and Bavisimo
Ingenia Therapeutics (Ingenia), a developer of treatments for microvascular diseases that has begun the public offering process for a KOSDAQ listing, has declared a paradigm shift in the age-related m…
Technology
KOSDAQ Biotech Rally...Alteogen Soars on European Patent Win [K-bio Pulse]
On July 23, the domestic stock market surged as expectations for artificial intelligence (AI) investments combined with strong momentum in healthcare and biotechnology stocks. The tech-heavy KOSDAQ ma…
Technology
[Bio Spotlight] Alteogen Inc. Soars After Shaking Off Patent Shackles… SAM CHUN DANG PHARM CO. LTD Warns Against 'FDA Mirage'
On the 23rd, the domestic stock market surged across the board, driven by expectations of expanded investment in artificial intelligence (AI) and a rally in biotech stocks. In particular, the KOSDAQ m…
Lifestyle
[Blue Ocean Veterinary Medical Devices] ④ Precision Biosensor Inc. on the Verge of Reaching 10 Billion Won in Veterinary Diagnostics Sales
As medical technology advances, the treatment of human diseases is evolving toward “personalized” and “precision medicine.” Consequently, demand for personalized treatment and precision medicine is no…
Lifestyle
Will SamilPharmaceutical Benefit from TG-C’s Phase 3 Setback?…Revaluation of Rights to the ‘World’s First DMOAD’
The value of the exclusive domestic distribution rights for “Lorecivivint,” a new osteoarthritis drug secured by SamilPharmaceutical(000520), is expected to be reevaluated. This follows the failure of…
Technology
Diagnostics Rally Despite Kolon TissueGene Trial Setback [K-Bio Pulse]
Investor sentiment across South Korea’s pharmaceutical and life sciences sectors remained weak on July 22 following the Phase 3 setback for Kolon TissueGene’s osteoarthritis candidate TG-C.Kolon Tissu…
Lifestyle
NanoenTek,Inc. and NGeneBio Co., Ltd. Diagnostic Stocks Soar Amid Fallout from Kolon TissueGene, Inc.’s Clinical Trial Failure [Bio Spotlight]
On the 22nd, investor sentiment in the domestic pharmaceutical and life sciences sector Kolon TissueGene, Inc.(950160)continued to deteriorate in the wake of the failure of TG-C’s Phase 3 clinical tri…
Lifestyle
Controversy Over KOLON CORPORATION Inbosa’s “Fundamental Efficacy” Reignites... CEO Noh Moon-jong: “There Is No Problem with Its Efficacy”
Kolon TissueGene, Inc.(950160) Controversy surrounding the fundamental efficacy of TG-C (formerly Invossa), a cell-gene therapy for osteoarthritis, has reignited after the drug failed to demonstrate e…
Lifestyle
Investors Ask... What's Next After Record-Breaking Earnings? [In-Depth Look at Wise birds Inc. ③]
Wise birds Inc.(273060), which has successfully transformed itself from a traditional digital advertising agency into an AI-based advertising platform company, is drawing significant attention from th…